Algernon Pharmaceuticals to provide interim data from Ifenprodil Phase 2b/3 human study

 

Algernon Pharmaceuticals (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau discusses news with Steve Darling from Proactive that the company will be sharing interim data from its multi-national Ifenprodil Phase 2b/3 COVID-19 human study.

Mr. Moreau explains to Proactive that the interim data will consist of 75 patients on day 15 of the study and will be presented in a descriptive statistics format. Algernon Pharmaceuticals is projecting the data readout will be in the first week of December 2020.

Share via
Copy link
Powered by Social Snap